[The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
During the last few years an increased interest has been directed towards the application of a new class of cholesterol lowering substances, the HMG-CoA reductase inhibitors. Since preclinical trials with beagle dogs revealed lens opacifications, the necessity of drug safety studies arose. The paper presents the results of two drug safety studies concerning Simvastatin (45 patients) and Pravastatin (35 patients) after an application period of two years in patients with primary hypercholesterolemia type II. Besides ophthalmological examinations (every 6 month) Scheimpflug photographs of the anterior eye segment have been taken and the negatives subjected to microdensitometric image analysis. Neither the clinical parameters nor the results of Scheimpflug measurement showed drug induced changes at the eye until now. Based on these results cataractogenic side effects of the substances in question could not be proven.